髋关节置换后利伐沙班与低分子肝素预防下肢深静脉血栓的比较

Curative effect of rivaroxaban versus low molecular weight heparin to prevent deep venous thrombosis following total hip arthroplasty

背景:低分子肝素可显著降低髋关节置换后下肢深静脉血栓的发生率,但其因需皮下注射而存在局限性。目的:比较全髋关节置换后应用利伐沙班与低分子肝素预防下肢深静脉血栓疗效和安全性的差异。方法:58例全髋关节置换患者按随机数字表法分为2组,利伐沙班组28例,低分子肝素组(达肝素)30例。置换后行双下肢彩色多普勒检查评估DVT形成情况,并观察治疗期间出血情况。结果与结论:利伐沙班组与达肝素组患者在预防下肢深静脉血栓疗效上差异无显著性意义(P>0.05)。两组在治疗期间均无严重出血,置换后非严重出血差异也无显著性意义(P>0.05)。提示利伐沙班在预防全髋置换后下肢深静脉血栓的疗效与安全性上与低分子肝素作用相当。

BACKGROUND：Low molecular weight heparin can obviously reduce the incidence of deep venous thrombosis（DVT） following total hip arthroplasty（THA）.However,subcutaneous injection limits the application of low molecular weight heparin.OBJECTIVE：To observe the clinical effects and security of low molecular weight heparin and rivaroxaban against DVT after THA.METHODS：Totally 58 THA patients were randomized into two groups：rivaroxaban group with 28 cases and heparin group with 30 cases.Occurrence of DVT and bleeding were observed under color Doppler of lower limbs.RESULTS AND CONCLUSION：There was no statistics differences in DVT prevention and intraoperative bleeding between the two groups（P 0.05）.Rivaroxaban has similar effects to low molecular weight heparin on DVT prevention after THA.